Table 2 The life expectancy (LE), the lifetime employment duration (LED), and the relative loss of LED for patients with end stage kidney disease (Index) and their corresponding age-, sex-, and calendar year-matched referents (Reference)

Male

 Aged 25–34

28.7 (21.9–33.4)

47.9 (47.7–48.0)

19.2 (14.1–25.7)

11.6 (9.8–12.2)

24.0 (23.8–24.0)

12.4 (11.6–14.0)

52% (48–59%)

 35–40

19.7 (15.2–21.3)

40.9 (40.7–41.0)

21.2 (19.2–25.4)

8.1 (7.3–8.4)

18.1 (18.1–18.2)

10.0 (9.6–10.8)

55% (53–60%)

 41–45

14.7 (12.7–15.0)

35.8 (35.8–36.0)

21.1 (20.8–23.1)

6.2 (5.8–6.3)

14.0 (14.0–14.0)

7.8 (7.7–8.2)

56% (55–59%)

 46–50

11.3 (10.4–11.3)

31.7 (31.3–31.7)

20.4 (20.3–21.0)

4.9 (4.7–4.9)

10.4 (10.3–10.4)

5.5 (5.4–5.7)

53% (52–55%)

 51–55

9.6 (8.9–9.7)

27.5 (27.5–27.6)

17.9 (17.8–18.6)

3.6 (3.4–3.6)

6.9 (6.8–6.9)

3.3 (3.2–3.4)

48% (47–50%)

 56–60

7.9 (7.5–7.9)

23.5 (23.2–23.5)

15.6 (15.5–15.9)

2.0 (1.9–2.1)

3.5 (3.5–3.6)

1.5 (1.5–1.6)

43% (41–45%)

 61–64

7.0 (6.7–7.1)

19.9 (19.8–20.0)

12.9 (12.8–13.2)

0.7 (0.7–0.7)

1.0 (1.0–1.1)

0.3 (0.3–0.4)

32% (29–34%)

Female

 Aged 25–34

31.5 (21.4–36.5)

54.0 (53.8–54.1)

22.5 (17.1–31.5)

10.7 (9.2–11.1)

23.5 (23.4–23.6)

12.8 (12.4–14.2)

54% (52–61%)

 35–40

25.1 (19.2–28.1)

46.6 (46.4–46.6)

21.5 (16.4–27.0)

9.8 (8.9–10.2)

17.6 (17.5–17.6)

7.8 (7.4–8.6)

44% (42–49%)

 41–45

19.1 (16.6–20.4)

41.4 (41.3–41.5)

22.3 (18.9–24.8)

7.8 (7.4–8.0)

13.5 (13.5–13.6)

5.7 (5.5–6.2)

42% (41–46%)

 46–50

16.0 (14.5–16.5)

36.7 (36.6–36.8)

20.7 (20.1–22.2)

6.1 (5.7–6.1)

9.8 (9.7–9.8)

3.7 (3.6–4.0)

38% (37–41%)

 51–55

12.1 (11.1–12.5)

32.1 (32.0–32.2)

20.0 (19.6–20.9)

4.0 (3.8–4.1)

6.2 (6.1–6.2)

2.2 (2.1–2.4)

36% (34–39%)

 56–60

9.6 (9.1–9.9)

27.4 (27.4–27.5)

17.8 (17.5–18.3)

2.0 (1.9–2.0)

3.0 (2.9–3.0)

1.0 (0.9–1.1)

34% (32–36%)

 61–64

7.6 (7.4–7.8)

23.3 (23.2–23.4)

15.7 (15.6–15.9)

0.6 (0.6–0.6)

0.8 (0.8–0.8)

0.2 (0.2–0.2)

25% (22–28%)